TY  - JOUR
A1  - Korkusuz, Hüdayi
A1  - Fehre, Niklas
A1  - Sennert, Michael
A1  - Happel, Christian
A1  - Grünwald, Frank
T1  - Early assessment of high-intensity focused ultrasound treatment of benign thyroid nodules by scintigraphic means
T2  - Journal of Therapeutic Ultrasound
N2  - Background: High-intensity focused ultrasound (HIFU) allows to inflict intracorporal thermal lesions without penetrating the skin or damaging the surrounding tissue. This analysis intends to assess the magnitude of HIFU-induced ablations within benign thyroid nodules using scintigraphic imaging with 99mTc.
Methods: Ten cold, hot, or indifferent nodules were treated using multiple pulses of HIFU to induce temperatures of around 85°C within the ablation zone. Pre- and posttreatment, uptake values of 99mTc pertechnetate or 99mTc-MIBI were recorded. The pre-post reduction of nodular uptake was evaluated to assess ablation magnitude.
Results: Relative nodular uptake in relation to total thyroidal uptake decreased after one session of HIFU in all cases. Median 99mTc-MIBI uptake reduction was 35.5% (ranging from 11% to 57%; p < 0.1), while 99mTc-pertechnetate scintigraphy showed a median uptake reduction of 27% (range 10% to 44%; p < 0.1). No major complications were observed.
Conclusions: HIFU appears to be safe and is an easy to perform means of thermal ablation. This study shows that HIFU treatment in thyroidal nodules can be evaluated by scintigraphic means shortly after the intervention. Due to small sample size, the exact magnitude of HIFU ablation efficiency in thyroidal nodules remains a value to beassessed in a larger study.
KW  - high-intensity focused ultrasound ablation
KW  - thyroid nodule
KW  - ablation techniques
KW  - radionuclide imaging
KW  - 99mTc-MIBI
KW  - 99mTc-pertechnetate
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/35375
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-353751
SN  - 2050-5736
N1  - © 2014 Korkusuz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
VL  - 2
IS  - Art. 18
SP  - 1
EP  - 10
PB  - Biomed Central
CY  - London
ER  -